CY1114634T1 - SP35 OPTIONS AND USES OF THESE - Google Patents

SP35 OPTIONS AND USES OF THESE

Info

Publication number
CY1114634T1
CY1114634T1 CY20131101031T CY131101031T CY1114634T1 CY 1114634 T1 CY1114634 T1 CY 1114634T1 CY 20131101031 T CY20131101031 T CY 20131101031T CY 131101031 T CY131101031 T CY 131101031T CY 1114634 T1 CY1114634 T1 CY 1114634T1
Authority
CY
Cyprus
Prior art keywords
antibodies
endogenous
oligodendrocytes
vertebrate
treatment
Prior art date
Application number
CY20131101031T
Other languages
Greek (el)
Inventor
Sha Mi
R Blake Pepinsky
Zhaohui Shao
Christilyn P Graff
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06786428.0A external-priority patent/EP1904104B1/en
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of CY1114634T1 publication Critical patent/CY1114634T1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ενδογενής SΡ35 είναι ένας αρνητικός ρυθμιστής για νευρωνική επιβίωση, επαναδημιουργία άξονα, διαφοροποίηση και μυελίνωση ολιγοδενδροκυττάρου (αρνητικός ρυθμιστής). Μόρια που αναστέλλουν λειτουργία ενδογενούς SΡ35 όπως αντι-SΡ35 αντισώματα μπορεί να χρησιμοποιηθούν ως θεραπευτικές ουσίες για τη θεραπεία δυσλειτουργίας νευρώνα και ολιγοδενδροκυττάρου. Η παρούσα εφεύρεση παρέχει αντισώματα ειδικά για SΡ35 και μεθόδους χρήσης τέτοιων αντισωμάτων ως ανταγωνιστών λειτουργίας ενδογενούς SΡ35. Η εφεύρεση περαιτέρω παρέχει ειδικά, λαμβανόμενα από υβρίδωμα και συλλογή φάγου, μονοκλωνικά αντισώματα, νουκλεϊνικά οξέα που κωδικοποιούν αυτά τα αντισώματα και φορείς και κύτταρα ξενιστές που περιλαμβάνουν αυτά τα αντισώματα. Η εφεύρεση περαιτέρω παρέχει μεθόδους προαγωγής, επιβίωσης και μυελίνωσης ολιγοδενδροκυττάρου σε ένα σπονδυλωτό, που περιλαμβάνουν χορήγηση σε ένα σπονδυλωτό που έχει ανάγκη μιας τέτοιας θεραπείας μιας αποτελεσματικής ποσότητας ενός αντι-SΡ35 αντισώματος.Endogenous SP35 is a negative regulator for neuronal survival, axon regeneration, differentiation and myelogenesis of oligodendrocytes (negative regulator). Molecules that inhibit endogenous SP35 function such as anti-SP35 antibodies can be used as therapeutic agents for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for SP35 and methods of using such antibodies as functional antagonists of endogenous SP35. The invention further provides, in particular, derived from hybridoma and phage collection, monoclonal antibodies, nucleic acids encoding these antibodies, and host vectors and cells comprising these antibodies. The invention further provides methods for promoting, survival and myelination of oligodendrocytes in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-SP35 antibody.

CY20131101031T 2005-07-08 2013-11-21 SP35 OPTIONS AND USES OF THESE CY1114634T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69733605A 2005-07-08 2005-07-08
US77190006A 2006-02-10 2006-02-10
US81452206A 2006-06-19 2006-06-19
EP06786428.0A EP1904104B1 (en) 2005-07-08 2006-07-07 Sp35 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CY1114634T1 true CY1114634T1 (en) 2016-10-05

Family

ID=58448824

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101031T CY1114634T1 (en) 2005-07-08 2013-11-21 SP35 OPTIONS AND USES OF THESE

Country Status (1)

Country Link
CY (1) CY1114634T1 (en)

Similar Documents

Publication Publication Date Title
CY1120285T1 (en) Sp35 antibodies and their uses
PH12014500347A1 (en) Sp35 antibodies and uses thereof
WO2010005570A3 (en) Compositions comprising antibodies to lingo or fragments thereof
EA200801509A1 (en) HUMAN MONOCLONAL ANTIBODIES TO PROTEINTHYROSINKINASE 7 (PTK7) AND METHODS OF APPLICATION OF ANTIBODIES AGAINST PTK7
EA200800229A1 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST LIGAND-1 PROGRAMMED CELL DECLINATION (PD-L1)
JOP20190017B1 (en) Human cgrp receptor binding antibodies
NO346167B1 (en) Humanized, glycome engineered Type II anti-CD20 antibody and use thereof, as well as host cell and pharmaceutical composition
EA200800953A1 (en) HUMAN MONOCLONAL ANTIBODIES TO CD70
SG170080A1 (en) Human monoclonal antibodies to o8e
DE602005027399D1 (en) FOR HUMAN MATRIPTASE SPECIFIC TIE PROTEINS
CO6180445A2 (en) ANTI NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO THE NOTCH3 GENE
WO2007039818A8 (en) Antigen binding molecules having modified fc regions and altered binding to fc receptors
EA200800094A1 (en) ANTIBODIES CD19 AND THEIR USE
ATE492563T1 (en) COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13
CU23719A3 (en) ANTIBODY AND IMMUNOCATE WITH NEUTRALIZING ACTIVITY OF RABIA VIRUS, NUCLEIC ACID MOLECULE AND VECTOR
ATE482234T1 (en) ANTIBODIES TO KDR, THEIR PRODUCTION AND USES
AR047729A1 (en) THERAPEUTIC ANTIBODIES THAT BIND APOLIPOPROTEIN E (APOE)
RU2012101485A (en) BESPECIFIC FOUR-PRINCIPAL ANTIGEN-BINDING PROTEINS
NZ590991A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA200901436A1 (en) Antigen-binding proteins that bind PAR-2
EA200401453A1 (en) MOLECULES OF CELLULAR RECOGNITION ON CELLULAR SURFACE CONTAINING IMMUNOGLOBULIN DOMAIN
ATE535546T1 (en) HUMAN MONOCLONAL ANTIBODIES THAT BIND SPECIFICALLY TO IFG-II
CY1114634T1 (en) SP35 OPTIONS AND USES OF THESE
ATE336501T1 (en) CHI-CONOTOXIN PEPTIDES AS INHIBITORS OF NEURONAL AMINE TRANSPORTERS
ATE466870T1 (en) PEPTIDES AND THEIR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES